[1] 李莹.免疫系统在癌症治疗中的两面性[J].现代预防医学,2006,33(9):1565-1567. [2] 李国玲,林华笙,韩雪飞,等.恶性肿瘤患者的免疫学变化[J].中华临床新医学,2004,4(1):9-10. [3] de Visser KE,Coussens LM.The interplay between innate and adaptive immunity regulates cancer development[J].Cancer Immunol Immunother,2005,54(11):1143-4452. [4] Malmberg KJ.Effective immunotherapy against cancer:a question of overcoming immune suppression and immune escape[J].Cancer Immunol Immunother,2004,53:879-892. [5] Mamessier E,Sylvain A,Bertucci F,et al.Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition[J].Cancer Res,2011,71(21):6621-6632. [6] Ito N,Nakamura H,Metsugi H,et al.Dissociation between T helper type 1 and type 2 differentiation and cytokine production in tumor-infiltrating lymphocytes in patients with lung cancer[J].Surg Today,2001,31(5):390-394. [7] Mahajan R,El-Omar EM,Lissowska J,et al.Genetic variants in T helper cell type 1,2 and 3 pathways and gastric cancer risk in a Polish population[J].Jpn J Clin Oncol,2008,38(9):626-633. [8] Sun Y,Qian C,Peng D,et al.Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone[J].Hum Gene Ther,2000,11(1):127-138. [9] De Monte L,Reni M,Tassi E,et al.Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer[J].J Exp Med,2011,208(3):469-478. [10] Ehi K,Ishigami S,Masamoto I,et al.Analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells of sentinel lymph nodes in breast cancer[J].Oncol Rep,2008,19(3):601-607. [11] 盛磊,阿仙姑·哈斯木,刘开江,等.维吾尔族妇女宫颈病变病理进程与降钙素相关肽α表达的关系[J].癌变·畸变·突变,2011,23(4):287-290. [12] Miyazaki T,Liu ZJ,Kawahara A,et al.Three distinct IL-2 signaling pathways mediated by bcl-2,c-myc,and lck cooperate in hematopoietic cell proliferation[J].Cell,1995,81(2):223-231. [13] Shevach EM.Application of IL-2 therapy to target T regulatory cell function[J].Trends Immunol,2012,33(12):626-632. [14] Lan RY,Selmi C,Gershwin ME.The regulatory,inflammatory,and T cell programming roles of interleukin-2(IL-2)[J].J Autoimmun,2008,31(1):7-12. [15] Gruenbacher G,Gander H,Nussbaumer O,et al.IL-2 costimulation enables statin-mediated activation of human NK cells,preferentially through a mechanism involving CD56+ dendritic cells[J].Cancer Res,2010,70(23):9611-9620. [16] Kim MT,Richer MJ,Gross BP,et al.Enhancing dendritic cell-based immunotherapy with IL-2/monoclonal antibody complexes for control of established tumors[J].Immunol,2015,195(9):4537-4544. [17] Kang TH,Mao CP,He L,et al.Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+T cells in the tumor loci and enhanced anti-tumor effects[J].PLoS One,2012,7(4):e35141. [18] Geginat J,Larghi P,Paroni M,et al.The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer[J/OL].Cytokine Growth Factor Rev,2016.doi:10.1016/j.cytogfr.2016.02.003. [19] Ma X,Yan W,Zheng H,et al.Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells[J/OL].F1000 Res,2015.doi:10.12688/f1000 research.7010.1. [20] Couper KN,Blount DG,Riley EM.IL-10:the master regulator of immunity to infection[J].J Immunol,2008,180(9):5771-5777. [21] Trifunović 1,Miller L,DebeljakŽ,et al.Pathologic patterns of interleukin 10 expression-a review[J].Biochem Med (Zagreb),2015,25(1):36-48. |